Oncotype DX Breast Cancer Testing
Estimated value
£273k
Awarded value
£273k
Awarded 02 Mar 2026
Suppliers
1
Lots
1
1 awarded
Published
03 Mar 2026
Deadline 04 Feb 2026
Description
Oncotype DX is a validated genomic assay recommended by NICE (DG34) for guiding chemotherapy decisions in specific cohorts of early breast cancer. It provides a Recurrence Score that stratifies patients into groups where chemotherapy is beneficial versus where endocrine therapy alone is sufficient.
Scope
- Reference
- CF-3414000D0O000000rwimUAA
- Total value
- £272,700 excluding VAT
- Commercial tool
- Standalone contract
- Contract dates
- 31 Mar 2026 to 30 Mar 2027
- CPV classifications
- 85111800
Submission & procedure
- Submission deadline
- 04 Feb 2026, 12:00 pm
Award details
Awarded supplier(s), contract period and value as published in the award notice.
Awarded value
£273k
Award date
02 Mar 2026
Contract start
31 Mar 2026
Contract end
30 Mar 2027
Awarded to